Global Wilson’s Disease Market: Industry Analysis & Outlook (2016-2020)
Wilson’s disease is a rare disease and is named after Kinnear Wilson who was the first to describe this disorder in 1912. His description terms the disease as a “progressive lenticular degeneration,” a hereditary, fatal neurological disease that is usually accompanied by chronic liver ailment that leads to a condition called cirrhosis. Wilson's disease is a hereditary disorder that leads to unwarranted accumulation of copper in crucial organs such as the liver, brain etc. The patient starts to accumulate copper from birth but diagnosis tends not to occur only in the later ages. The primary signs of Wilson’s disease become prominent usually between the ages of 12 and 23 years.
Wilson’s disease is caused by the mutation of a gene named ATP7B. Absent or reduced function of ATP7B protein leads to reduced elimination of copper into the bile. Wilson’s disease is inherited as an autosomal recessive trait, which means that in order to develop the disease one must inherit two procreations of the defective gene, one from each parent. If a person receives only one abnormal gene from either of the parents, he/she is not likely to get affected by the Wilson’s disease. Wilson’s disease may be difficult to primarily diagnose as the symptoms are alike to other health issues like heavy metal poisoning, hepatitis C, and cerebral palsy.
The important factors that are anticipated to drive the market include rising prices of chelators in the US, rising attractiveness of orphan drugs market, increasing global healthcare expenditure as well as spending on medicines. The noteworthy trends in the market include falling number of prescriptions for Wilson’s disease, and the development of gene therapy as a potential cure for the disease. However, the market is confronted by crucial challenges such as under-diagnosis of the disease, lack of safety in treatments, poor compliance to current treatments and unmet efficacy needs.
This report provides a wide-ranging study of global Wilson’s disease market and also its key regional markets such as the US and Europe. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global Wilson’s disease industry is highly competitive consisting of several large corporations. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.
Wilson’s disease is caused by the mutation of a gene named ATP7B. Absent or reduced function of ATP7B protein leads to reduced elimination of copper into the bile. Wilson’s disease is inherited as an autosomal recessive trait, which means that in order to develop the disease one must inherit two procreations of the defective gene, one from each parent. If a person receives only one abnormal gene from either of the parents, he/she is not likely to get affected by the Wilson’s disease. Wilson’s disease may be difficult to primarily diagnose as the symptoms are alike to other health issues like heavy metal poisoning, hepatitis C, and cerebral palsy.
The important factors that are anticipated to drive the market include rising prices of chelators in the US, rising attractiveness of orphan drugs market, increasing global healthcare expenditure as well as spending on medicines. The noteworthy trends in the market include falling number of prescriptions for Wilson’s disease, and the development of gene therapy as a potential cure for the disease. However, the market is confronted by crucial challenges such as under-diagnosis of the disease, lack of safety in treatments, poor compliance to current treatments and unmet efficacy needs.
This report provides a wide-ranging study of global Wilson’s disease market and also its key regional markets such as the US and Europe. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global Wilson’s disease industry is highly competitive consisting of several large corporations. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.
1. MARKET OVERVIEW
1.1 Introduction
1.2 Causes
1.3 Symptoms
1.3.1 Hepatic Symptoms
1.3.2 Neurological Symptoms
1.3.3 Ophthalmic Symptoms
1.3.4 Other Symptoms
1.4 Diagnosis
1.5 Treatment through Medications
1.5.1 D-penicillamine
1.5.2 Trientine
1.5.3 Zinc Salts
1.5.4 Ammonium tetrathiomolybdate
1.5.5 Bis-Choline Tetrathiomolybdate – Decuprate
2. GLOBAL MARKET
2.1 Global Orphan Drugs Market Revenue – Actuals
2.2 Global Orphan Drugs Market Revenue – Forecast
2.3 Wilson’s Disease Prevalence by Region
2.4 Wilson’s Disease Market by Treatment – New Patients
2.5 Wilson’s Disease Market by Treatment – Experienced Patients
2.6 Global Decuprate Revenue – Forecast
2.7 Global Liver Transplantation by Region
3. REGIONAL MARKETS
3.1 Europe
3.1.1 Wilson’s Disease Prevalence – Forecast
3.1.2 Wilson’s Disease Market by Treatment
3.1.3 Wilson’s Disease Patients Treated with Zinc – Forecast
3.1.4 Wilson’s Disease Patients Treated with Chelators – Forecast
3.1.5 Wilson’s Disease Patients Treated with Decuprate – Forecast
3.2 The US
3.2.1 Wilson’s Disease Prevalence – Forecast
3.2.2 Wilson’s Disease Market by Treatment
3.2.3 Wilson’s Disease Patients Treated with Zinc – Forecast
3.2.4 Wilson’s Disease Patients Treated with Chelators – Forecast
3.2.5 Chelators Market Revenue – Actuals
3.2.6 Chelators Market Revenue – Forecast
3.2.7 Wilson’s Disease Patient Treated with Decuprate – Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Prices of Chelators in the US
4.1.2 Rising Attractiveness of Orphan Drug Market
4.1.3 Rising Global Spending on Medicines
4.1.4 Increasing Healthcare Expenditure
4.2 Trends
4.2.1 Falling Number of Prescription for Chelators
4.2.2 Gene Therapy for Wilson’s Disease
4.3 Challenges
4.3.1 Under-Diagnosis of the Disease
4.3.2 Lack of Safety in Treatments
4.3.3 Poor Compliance of Patients to Current Treatments
4.3.4 Unmet Efficacy Needs
5. COMPETITIVE LANDSCAPE
5.1 Competition by Revenue
5.2 Competition by Market Capitalization
5.3 Competition by Profitability
6. COMPANY PROFILES
6.1 Valeant Pharmaceuticals Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Meda AB
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Teva Pharmaceuticals
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Wilson Therapeutics
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
1.1 Introduction
1.2 Causes
1.3 Symptoms
1.3.1 Hepatic Symptoms
1.3.2 Neurological Symptoms
1.3.3 Ophthalmic Symptoms
1.3.4 Other Symptoms
1.4 Diagnosis
1.5 Treatment through Medications
1.5.1 D-penicillamine
1.5.2 Trientine
1.5.3 Zinc Salts
1.5.4 Ammonium tetrathiomolybdate
1.5.5 Bis-Choline Tetrathiomolybdate – Decuprate
2. GLOBAL MARKET
2.1 Global Orphan Drugs Market Revenue – Actuals
2.2 Global Orphan Drugs Market Revenue – Forecast
2.3 Wilson’s Disease Prevalence by Region
2.4 Wilson’s Disease Market by Treatment – New Patients
2.5 Wilson’s Disease Market by Treatment – Experienced Patients
2.6 Global Decuprate Revenue – Forecast
2.7 Global Liver Transplantation by Region
3. REGIONAL MARKETS
3.1 Europe
3.1.1 Wilson’s Disease Prevalence – Forecast
3.1.2 Wilson’s Disease Market by Treatment
3.1.3 Wilson’s Disease Patients Treated with Zinc – Forecast
3.1.4 Wilson’s Disease Patients Treated with Chelators – Forecast
3.1.5 Wilson’s Disease Patients Treated with Decuprate – Forecast
3.2 The US
3.2.1 Wilson’s Disease Prevalence – Forecast
3.2.2 Wilson’s Disease Market by Treatment
3.2.3 Wilson’s Disease Patients Treated with Zinc – Forecast
3.2.4 Wilson’s Disease Patients Treated with Chelators – Forecast
3.2.5 Chelators Market Revenue – Actuals
3.2.6 Chelators Market Revenue – Forecast
3.2.7 Wilson’s Disease Patient Treated with Decuprate – Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Prices of Chelators in the US
4.1.2 Rising Attractiveness of Orphan Drug Market
4.1.3 Rising Global Spending on Medicines
4.1.4 Increasing Healthcare Expenditure
4.2 Trends
4.2.1 Falling Number of Prescription for Chelators
4.2.2 Gene Therapy for Wilson’s Disease
4.3 Challenges
4.3.1 Under-Diagnosis of the Disease
4.3.2 Lack of Safety in Treatments
4.3.3 Poor Compliance of Patients to Current Treatments
4.3.4 Unmet Efficacy Needs
5. COMPETITIVE LANDSCAPE
5.1 Competition by Revenue
5.2 Competition by Market Capitalization
5.3 Competition by Profitability
6. COMPANY PROFILES
6.1 Valeant Pharmaceuticals Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Meda AB
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Teva Pharmaceuticals
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Wilson Therapeutics
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
LIST OF CHARTS
Global Orphan Drugs Market Revenue – Actuals (2012-2015)
Global Orphan Drugs Market Revenue – Forecast (2016-2020)
Wilson’s Disease Prevalence by Region (2015)
Wilson’s Disease Market by Treatment – New Patients (2015)
Wilson’s Disease Market by Treatment – Experienced Patients (2015)
Global Decuprate Revenue – Forecast (2020-2025)
Global Liver Transplantation by Region (2015)
Wilson’s Disease Prevalence – Forecast (2015-2020)
Wilson’s Disease Market by Treatment (2015)
Wilson’s Disease Patients Treated with Zinc - Forecast (2015-2020)
Wilson’s Disease Patients Treated with Chelators - Forecast (2015-2020)
Wilson’s Disease Patients Treated with Decuprate - Forecast (2020-2025)
Wilson’s Disease Prevalence – Forecast (2015-2020)
Wilson’s Disease Market by Treatment (2015)
Wilson’s Disease Patients Treated with Zinc – Forecast (2015-2020)
Wilson’s Disease Patients Treated with Chelators – Forecast (2015-2020)
Chelators Market Revenue – Actuals (2012-2015)
Chelators Market Revenue – Forecast (2016-2020)
Wilson’s Disease Patient Treated with Decuprate - Forecast (2020-2025)
Average Price of Chelators in the US (2012-2015)
Median Cost of Phase III Trials (2015)
Global Spending on Medicines (2010-2015)
Global Healthcare Expenditure Per Capita (2011-2015)
Number of Prescriptions for Chelators in the US (2011-2015)
Revenue Comparison of Key Players (2015)
Market Capitalization Comparison of Key Players (2015)
Net Profit Margin Comparison of Key Players (2015)
Revenue Share by Business Segments, Valeant Pharmaceuticals (2015)
Revenue and Net Income, Valeant Pharmaceuticals (2013-2015)
Revenue Share by Business Segments, Meda AB (2015)
Revenue and Net Income, Meda AB (2014-2015)
Revenue Share by Business Segments, Teva Pharmaceuticals (2015)
Revenue and Net Income, Teva Pharmaceuticals (2013-2015)
Revenue and Net Income, Wilson Therapeutics (2013-2015)
Global Orphan Drugs Market Revenue – Actuals (2012-2015)
Global Orphan Drugs Market Revenue – Forecast (2016-2020)
Wilson’s Disease Prevalence by Region (2015)
Wilson’s Disease Market by Treatment – New Patients (2015)
Wilson’s Disease Market by Treatment – Experienced Patients (2015)
Global Decuprate Revenue – Forecast (2020-2025)
Global Liver Transplantation by Region (2015)
Wilson’s Disease Prevalence – Forecast (2015-2020)
Wilson’s Disease Market by Treatment (2015)
Wilson’s Disease Patients Treated with Zinc - Forecast (2015-2020)
Wilson’s Disease Patients Treated with Chelators - Forecast (2015-2020)
Wilson’s Disease Patients Treated with Decuprate - Forecast (2020-2025)
Wilson’s Disease Prevalence – Forecast (2015-2020)
Wilson’s Disease Market by Treatment (2015)
Wilson’s Disease Patients Treated with Zinc – Forecast (2015-2020)
Wilson’s Disease Patients Treated with Chelators – Forecast (2015-2020)
Chelators Market Revenue – Actuals (2012-2015)
Chelators Market Revenue – Forecast (2016-2020)
Wilson’s Disease Patient Treated with Decuprate - Forecast (2020-2025)
Average Price of Chelators in the US (2012-2015)
Median Cost of Phase III Trials (2015)
Global Spending on Medicines (2010-2015)
Global Healthcare Expenditure Per Capita (2011-2015)
Number of Prescriptions for Chelators in the US (2011-2015)
Revenue Comparison of Key Players (2015)
Market Capitalization Comparison of Key Players (2015)
Net Profit Margin Comparison of Key Players (2015)
Revenue Share by Business Segments, Valeant Pharmaceuticals (2015)
Revenue and Net Income, Valeant Pharmaceuticals (2013-2015)
Revenue Share by Business Segments, Meda AB (2015)
Revenue and Net Income, Meda AB (2014-2015)
Revenue Share by Business Segments, Teva Pharmaceuticals (2015)
Revenue and Net Income, Teva Pharmaceuticals (2013-2015)
Revenue and Net Income, Wilson Therapeutics (2013-2015)
